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Abstract
Background: Germline mutations of the succinate dehydrogenase subunit B gene (SDHB) predispose carriers for 
paragangliomas, and current estimates of the chance of mutation carriers actually developing tumors (penetrance) are 
high. We evaluate the phenotype and penetrance of a germline SDHB mutation in a large and clinically well-
characterized paraganglioma family.
Methods: Following identification of the mutation in a 31 year old index-patient, extensive clinical screening was 
performed in mutation carriers to evaluate the presence of head and neck, thoracic and abdominal paragangliomas. 
Presymptomatic DNA testing was performed in 19 family members.
Results: DNA analysis detected 14 further SDHB mutation carriers. Three mutation carriers (median age 78 years) 
declined clinical surveillance, but had no clinical signs or symptoms associated with paragangliomas. The remaining 11 
mutation carriers (mean age 53, range 37-76 years) consented to clinical screening. In only two, aged 43 and 48 years, 
were subclinical vagal paragangliomas identified.
Conclusions: Only three of the fifteen mutation carriers in this family have developed paraganglioma, which results in 
a calculated penetrance of 26% at 48 years of age. This figure is lower than current estimates, and we conclude that the 
co-operation of this family allowed an almost complete attainment of mutation carriers, and the extensive clinical 
evaluation carried out allowed us to identify all affected individuals.
Background
Germline mutations in the succinate dehydrogenase
(SDH) subunit genes SDHB, SDHC, SDHD and SDHAF2
p r e d i s p o s e  c a r r i e r s  t o  t u m o r s  o f  t h e  p a r a g a n g l i a ,  t h e
paragangliomas [1]. Parasympathetic paragangliomas
arise in the head and neck, whereas sympathetic paragan-
gliomas are generally intrathoracic, retroperitoneal or
located in the adrenal medulla (pheochromocytoma).
Mutations of SDHD  are the most prominent cause of
head-and-neck paragangliomas, whereas mutations in
SDHB  frequently result in adrenal and extra-adrenal
paragangliomas, and related malignant disease [2-6].
Germline SDHB mutations show an autosomal domi-
nant inheritance pattern, but the full clinical implications
of SDHB mutations have remained obscure since most
studies to date have described predominantly affected
index cases [3,4]. SDHB germline mutation carriers often
present as apparently sporadic patients, i.e. with a nega-
tive family history for paragangliomas. There is no evi-
dence that these patients are genuine de novo cases and
when studied, other mutation carriers can usually be
identified in the family. While it is recognized that the
penetrance of SDHB  mutations is incomplete and age
dependent [1,3,4], particularly in comparison with
SDHD, the current estimates are likely to be inflated
because many mutation carriers remain asymptomatic.
Only two other large families has been described in
which presymptomatic family members were identified
by genetic screening [7,8].
The aim of the current study was to assess the pheno-
type and penetrance of a germline SDHB  splice-site
mutation (c.423+1G > A, intron 4) in a large Dutch para-
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ganglioma family. This family was identified following
DNA analysis in an apparently sporadic index-patient
with an extra-adrenal paraganglioma. We carried a full
clinical and genetic assessment in all consenting family
members.
Methods
Informed consent was obtained for DNA testing accord-
ing to protocols approved by the local ethics review
board. Mutation carriers were referred to the outpatient
clinic of the departments of Endocrinology and Otorhi-
nolaryngology of the Leiden University Medical Center,
which is a tertiary referral center for paragangliomas. All
patients were included in a previously described stan-
dardized follow-up protocol [6,9,10] and gave permission
for publication of clinical test results. Briefly, SDHB
mutation carriers were seen at least yearly, and cate-
cholamine screening was carried out in duplicate 24
hours urine under strict dietary medication regulations.
Epinephrine, norepinephrine, metanephrine, normeta-
nephrine, dopamine, VMA and 3-methoxy-tyramine
excretion in 24 h urine were quantified as described
[6,9,10]. Reference ranges were: epinephrine < 0.16 μmol/
24 h, norepinephrine 0.06-0.47 μmol/24 h, metanephrine
33-90 μmol per mol creatinine, normetanephrine 64-260
μmol per mol creatinine, dopamine 0.46-3.40 μmol/24 h,
VMA < 30 μmol/24 h, and 3-methoxy-tyramine 45-197
μmol per mol creatinine.
In cases of excessive secretion, MIBG scanning and
additional whole-body MRI and/or CT imaging were per-
formed. Whole-body MRI and/or CT imaging are per-
formed at least every two years regardless of
catecholamine levels. The head and neck region were
examined annually by an Ear-Nose-Throat (ENT) - sur-
geon and all head and neck paragangliomas were assessed
yearly by MRI. Presymptomatic mutation carriers have an
MRI of the head and neck region every 3-5 years.
DNA analysis and haplotyping
Sequence analysis of the coding region including the
splice sites of the SDHB gene was performed according to
standard procedures (details available upon request),
using the NT_004610.18 reference sequence [11]. The
mutation was described following the nomenclature
guidelines of the Human Genome Variation Society http:/
/www.hgvs.org/. Haplotyping was performed following
standard procedures (details available upon request) with
the following markers: D1S436, D1S2697, D1S170,
D1S3669, D1S2826 and D1S2644. The distance between
the last and the first marker (D1S436 and D1S2644) is ~
3.35 Mb.
Statistics
Penetrance was calculated using the reverse Kaplan-
Meier method. Kaplan-Meier survival tables included all
mutation carriers, including the three aged individuals
who declined screening. 95% confidence intervals are also
depicted.
Results
The index patient, a 31-year old man, was referred for
evaluation of hypertension (III-8, figure 1). His unmedi-
cated blood pressure was 165/105 mmHg, without parox-
ysmal episodes. Twenty four-hour urine analysis showed
Figure 1 Pedigree with clinical data. The arrow shows the index patient. The non-carriers have been collapsed to minimize recognition of the ped-
igree.+, mutation present; -, mutation absent; C, clinical screening; N, no symptoms (but not screened); RC, rectal carcinoma; Ov, ovarian carcinoma; 
EC, endometrial carcinoma; BC, breast cancer (tumors with age at diagnosis in years).Hes et al. BMC Medical Genetics 2010, 11:92
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repeatedly increased excretion of VMA (58-80 μmol/24
hr) and norepinephrine (3.86-7.29 μmol/24 hr). ENT
examination and MRI produced no evidence of head and
neck paraganglioma. Abdominal MRI showed a 3 cm
mass between the aorta and inferior vena cava, negative
by  l23I-MIBG-scan. Following preoperative alpha- and
betablockade, the mass was resected and the histological
diagnosis was paraganglioma. After removal of the tumor,
blood pressure and catecholamines normalized.
The patient's family history was negative for paragan-
glioma, but DNA analysis revealed a mutation in the
SDHB gene, c.423+1 G > A, a splice-site mutation previ-
ously identified and shown by us to lead to mis-splicing
[11]. This mutation has subsequently been identified in
other paraganglioma patients and is known to be patho-
genic.
Subsequently, 19 family members of the index patient
consented in presymptomatic mutation screening. Five
non-carriers and 14 carriers were identified, of whom 11
consented to clinical screening. The remaining three
mutation carriers were of a median age of 78 years (II-
2,3,5), declined clinical surveillance, but had no clinical
symptoms to suggest paraganglioma. Screening resulted
in the identification of two family members (III-9 and III-
3) with subclinical vagal paragangliomas.
The sibling of the index patient (III-9), a 42-year old
man, had no clinical indication of paraganglioma and no
suspicious symptoms, with lightly elevated blood pres-
sure (140/85 mmHg), but MRI of the neck region showed
a right-sided vagal paraganglioma. Analysis of 24-hour
urine showed a slightly increased excretion of VMA (34
μmol/24 hours). MIBG- and MRI-scans of the abdomen
showed two small lesions (diameter 5 mm) with
increased uptake on MIBG, possibly para-aortic paragan-
gliomas. The lesions were laparoscopically removed and
the histopathological diagnosis was ganglioneuroma.
Postoperatively, urinary catecholamines normalized.
Patient (III-3), an asymptomatic 48-year old male
cousin of the index-patient, had recent hypertension
(140/85 mmHg). An MRI of the head-and-neck area
showed a right-sided vagal paraganglioma. 24-hour urine
analysis revealed increased excretion of the dopamine
metabolite 3M-tyramine (688 and 938 μmol per mol cre-
atinine), without increased excretion of other cate-
cholamines. Abdominal and mediastinal MRI showed no
paraganglioma.
In addition to the described patients (III-3,8,9), the
remaining mutation carriers underwent clinical evalua-
tion for paragangliomas. These subjects had a mean age
of 53 years (range 37-76 years), and despite full body
imaging and extensive biochemical analyses, no indica-
tions for the presence of paragangliomas or pheochromo-
cytomas could be found. It is worth noting that including
the three symptom-free carriers who declined screening,
six mutation carriers aged 66-81 years were negative by
clinical screening or by lack of any manifestations of
paragangliomas.
Kaplan-Meier analysis of the mutation cases showed a
penetrance of 26% at 48 years for the germline SDHB
c.423+1G > A mutation, indicating a remarkable reduced
penetrance (Figure 2).
Additional SDHB c.423+1G > A mutation carriers
In addition to the family described above, four Dutch
paraganglioma patients were found to be carriers of the
c.423+1G > A mutation. Since these patients were not
known to be related to the family, we carried out micro-
satellite marker analysis to determine if the mutation was
located on a shared haplotype, which would indicate a
(distant) family relationship. Founder mutations are well
known in the Dutch population and the SDHD  D92Y
mutation is a striking example [12]. As expected, a shared
haplotype was found in the family, and the same haplo-
type was also found in all four sporadic patients. This
marker haplotype has a frequency of less than 1% in the
Dutch population and the likelihood of five unrelated
cases carrying this haplotype is > 1.1 ×10-10, indicating
that all patients are related.
Discussion
This study describes a large SDHB-related family, in
which an extensive and detailed clinical and genetic
screening program has been carried out. The identifica-
tion of a relatively large number of presymptomatic
mutation carriers provides evidence for a lower pene-
trance of an SDHB mutation than suggested in previous
studies. In addition, haplotype analysis in four apparently
sporadic patients demonstrated that these cases are
related to the described family, again reinforcing the pre-
viously only suggestive evidence that behind every para-
ganglioma patient with an SDHB mutation, many
Figure 2 Kaplan-Meier curve of age-related penetrance of SDHB 
c.423+1G > A carriers. Thin lines represent 95% confidence intervals.Hes et al. BMC Medical Genetics 2010, 11:92
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asymptomatic mutation carriers remain under the clini-
cal radar.
Our observation that only three of fifteen SDHB muta-
tion carriers developed paragangliomas indicates a pene-
trance of only 26% at 48 years, is lower than previous
studies (50% - 77% at 50 years) [3,4]. The fact that SDHB
mutation carriers often present as apparently non-famil-
ial cases was suggestive of reduced penetrance [4,13-15],
and even founder mutations of SDHB have presented ini-
tially in isolated cases or families [16,17].
Any accurate estimation of penetrance requires full
clinical screening of as many genetically affected family
members of index cases as will co-operate. Even under
such ideal scenarios, the possibility of bias remains in that
unaffected family members are less likely to be inclined to
undergo extensive clinical investigation. The estimation
of penetrance based on index cases, as is commonly prac-
ticed, is tempting but erroneous, and studies that include
only a limited number of additional family members will
also only provide an approximation to the true pene-
trance. Initial estimates of penetrance are often inflated,
and tend to decline as more extensive families are evalu-
ated. Our study once again reiterates that only well-con-
ducted family studies can be used to assess penetrance.
The only other extensive study carried out to date on
the penetrance of SDHB, by Solis et al., reported a pene-
trance of 35% at 50 yrs [7]. This estimate is higher than
t h a t  r e p o r t e d  h e r e  b u t  m a y  a l s o  b e  u p w a r d l y  b i a s e d
because 18 mutation carriers declined clinical screening,
and these may have been individuals who felt no pressing
need to undergo screening. It is worth noting that Solis et
al. were able to diagnose 11 paraganglioma patients
amongst 41 mutation carriers (27%).
An obvious caveat of our study is the size of the family
and the low number of affected patients, reflected in the
wide confidence intervals of the Kaplan-Meier analysis,
and also the current age of some mutation carriers. In
addition, a possible mutation specific genotype-pheno-
type effect may exist with some normal transcript being
produced from the mutated transcript, although this is
unlikely in light of the importance of the consensus splice
donor site. Another, although less probable caveat, is that
of a possible family-specific modifier of penetrance. The
further elucidation of the true penetrance of SDHB muta-
tions requires the description of many more families in a
manner similar to that described here.
Conclusions
In summary, we described a large and extensively
screened family with a germline SDHB mutation. Thor-
ough analysis of large cohorts of both symptomatic and
presymptomatically detected mutation carriers and hap-
lotyping are required to further elucidate the natural his-
tory of SDH-associated disease.
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